Канада - Енглески - Health Canada

omega laboratories limited - scopolamine hydrobromide - liquid - 0.6mg - scopolamine hydrobromide 0.6mg - antimuscarinics antispasmodics

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

tps - scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - take one tablet orally as directed by your physician as needed for symptoms of panic or anxiety. do not exceed two tablets per day.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - butylscopolamine bromide (unii: 0gh9jx37c8) (butylscopolamine - unii:2z3e1of81v) - butylscopolamine bromide 20 mg in 1 ml - buscopan is indicated for the control of abdominal pain (colic) associated with spasmodic colic, flatulent colic, and simple impactions in horses. buscopan should not be used in impaction colics associated with ileus, or in horses with glaucoma.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

prasco laboratories - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - • glaucoma; • obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); • obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); • paralytic ileus, intestinal atony of the elderly or debilitated patient; • unstable cardiovascular status in acute hemorrhage; • severe ulcerative colitis especially if complicated by toxic megacolon; • myasthenia gravis; • hiatal hernia associated with reflux esophagitis; • in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings ). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsion

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - - glaucoma;  - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy);  - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.);  - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage;  - severe ulcerative colitis especially if complicated by toxic megacolon;  - myasthenia gravis;  - hiatal hernia associated with reflux esophagitis;  - in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings ). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

glaxosmithkline consumer healthcare holdings (us) llc - scopolamine (unii: dl48g20x8x) (scopolamine - unii:dl48g20x8x) - transderm scōp is indicated in adults for the prevention of: transderm scōp is contraindicated in patients with: risk summary available data from observational studies and postmarketing reports with scopolamine use in pregnant women have not identified a drug associated risk of major birth defects, miscarriage, or adverse fetal outcomes. avoid use of transderm scōp in pregnant women with severe preeclampsia because eclamptic seizures have been reported after exposure to scopolamine (see data). in animal studies, there was no evidence of adverse developmental effects with intravenous administration of scopolamine hydrobromide revealed in rats. embryotoxicity was observed in rabbits at intravenous doses producing plasma levels approximately 100 times the levels achieved in humans using a transdermal system. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - - glaucoma; - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage; - severe ulcerative colitis especially if complicated by toxic megacolon; - myasthenia gravis; - hiatal hernia associated with reflux esophagitis; - in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

tps - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - atenolol 25 mg in 25.25 mg - take one tablet sublingually or orally as directed by your physician as needed for symptoms of panic or anxiety. do not exceed two tablets per day.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

tps - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - propranolol hydrochloride 40 mg in 40.5 mg - take one tablet orally as directed by your physician as needed for symptoms of panic or anxiety. do not exceed two tablets per day.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

tps - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - take one tablet orally as directed by your physician as needed for symptoms of panic or anxiety. do not exceed two tablets per day.